Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Molecules ; 23(11)2018 Nov 11.
Article in English | MEDLINE | ID: mdl-30423862

ABSTRACT

64CuCl2 has recently been proposed as a promising agent for prostate cancer (PCa) theranostics, based on preclinical studies in cellular and animal models, and on the increasing number of human studies documenting its use for PCa diagnosis. Nevertheless, the use of 64CuCl2 raises important radiobiological questions that have yet to be addressed. In this work, using a panel of PCa cell lines in comparison with a non-tumoral prostate cell line, we combined cytogenetic approaches with radiocytotoxicity assays to obtain significant insights into the cellular consequences of exposure to 64CuCl2. PCa cells were found to exhibit increased 64CuCl2 uptake, which could not be attributed to increased expression of the main copper cellular importer, hCtr1, as had been previously suggested. Early DNA damage and genomic instability were also higher in PCa cells, with the tumoral cell lines exhibiting deficient DNA-damage repair upon exposure to 64CuCl2. This was corroborated by the observation that 64CuCl2 was more cytotoxic in PCa cells than in non-tumoral cells. Overall, we showed for the first time that PCa cells had a higher sensitivity to 64CuCl2 than healthy cells, supporting the idea that this compound deserved to be further evaluated as a theranostic agent in PCa.


Subject(s)
Chlorides/chemistry , Copper Radioisotopes/chemistry , Copper Radioisotopes/pharmacology , Theranostic Nanomedicine , Animals , Cell Line, Tumor , Copper Transport Proteins , DNA Damage , Disease Models, Animal , Gene Expression , Genomic Instability , Humans , Male , Metallochaperones/genetics , Metallochaperones/metabolism , Mice , Molecular Chaperones , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL